A recent study has implicated that sticky proteins associated with neurodegenerative diseases could be transferred in mouse models.
Scientists have created a vaccine containing monoclonal antibodies that are effective against several synthetic opioids, including carfentanil.
New research has revealed that gliomas in neurofibromatosis type 1 (NF1) patients may be effectively treated by immunotherapy.
A recent study has indicated that problem-solving activities do not protect against mental decline but instead, imparts a higher starting point from which decline is observed.
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
Three novel radiopharmaceuticals have been evaluated for their potential to be utilized in PET imaging of tau proteins in humans. The results of the study have the potential to improve the way we diagnose and treat Alzheimer’s disease.
This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
Research demonstrates that female mice display a unique pattern of fluctuation in sex hormones during the ovarian cycle that could be linked to cognitive impairments such as Alzheimer’s disease.
Want to find out what’s been happening this year? Editor, Sharon Salt, highlights the best of 2018’s neuroscience and neurology research in an A–Z.
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.